Lood van Niekerk

Lood van Niekerk

Auto-generated profile, based on publicly available information

Lood van Niekerk

Ginkgo Bioworks, Inc

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
PNPascal Notin
Pascal Notin
AKAaron W. Kollasch
Aaron W. Kollasch
DRDaniel Ritter
Daniel Ritter
LNLood van Niekerk
Lood van Niekerk
SPSteffanie Paul
Steffanie Paul
DMDebora S. Marks
Debora S. Marks
Predicting the effects of mutations in proteins is critical to many applications, from understanding genetic disease to designing novel proteins that can address our most pressing challenges in climate, agriculture and healthcare. Despite a surge in machine learning-based protein models to tackle these questions, an assessment of their respective benefits is challenging due to the use of distinct, often contrived, experimental datasets, and the variable performance of models across different protein families. Addressing these challenges requires scale. To that end we introduce ProteinGym, a large-scale and holistic set of benchmarks specifically designed for protein fitness prediction and design. It encompasses both a broad collection of over 250 standardized deep mutational scanning assays, spanning millions of mutated sequences, as well as curated clinical datasets providing high-quality expert annotations about mutation effects. We devise a robust evaluation framework that combines metrics for both fitness prediction and design, factors in known limitations of the underlying experimental methods, and covers both zero-shot and supervised settings. We report the performance of a diverse set of over 70 high-performing models from various subfields (eg., alignment-based, inverse folding) into a unified benchmark suite. We open source the corresponding codebase, datasets, MSAs, structures, model predictions and develop a user-friendly website that facilitates data access and analysis.

2 December 2025 in mAbs
Verified
Journal Article
Open access
AAAmmar Arsiwala
Ammar Arsiwala
RBRebecca Bhatt
Rebecca Bhatt
LNLood van Niekerk
Lood van Niekerk
PQPorfirio Quintero-Cadena
Porfirio Quintero-Cadena
XAXiang Ao
Xiang Ao
DBDavid W. Borhani
David W. Borhani
Antibodies must bind their targets with high affinity and specificity to achieve useful therapeutic activity. They must also possess suitable developability properties (e.g. thermostability, solubility, viscosity, polyreactivity) to ensure favorable manufacturing, formulation, and in vivo performance. Both binding and developability properties are inherent to a given antibody amino acid sequence. Identification or selection of antibodies possessing suitable-binding characteristics is now routine, and de novo computational design models, trained on extensive complementarity-determining region sequence and structural data, are rapidly improving. Developability properties, however, remain difficult to predict largely due to insufficient training data, with empirical testing being heavily used to avoid challenges in late-stage antibody development. To fill this gap, we built a high-throughput antibody developability assay platform designed to generate the large datasets needed to train improved machine learning (ML) models. We optimized and automated known developability assays, and developed a robust integrated data analytics pipeline. Here, we report data on 246 antibodies - representing 106 approved, 135 clinical-stage, and 5 preregistration/withdrawn molecules - across a panel of 10 developability assays, in a "tidy data" format suitable for AI/ML modeling. We used these data to develop an XGBoost ML model that better predicts similarity to approved antibodies compared to conventional use of developability warning thresholds. Additionally, we confirm that preliminary predictive models do improve with more training data. Our high-throughput PROPHET-Ab platform enables data generation at the scale needed to develop improved ML models to predict antibody developability.